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Background: To date, in Myotonic Dystrophy type 1 (DM1) the rehabilitative interventions have always been aimed
at muscle strengthening, increasing of fatigue resistance and improving of aerobic metabolism efficiency whereas
the electrical membrane fault has always been addressed pharmacologically. Neuromuscular electrical stimulation
(NMES) is a useful therapeutic tool in sport medicine and in the rehabilitation of many clinical conditions
characterized by motor impairment such as stroke, cerebral palsy and spinal cord injury.
The aim of our pilot study was to evaluate the effects of chronic electrical stimulation both on functional and
electrical properties of muscle in a small group of DM1 patients.
Methods: Five DM1 patients and one patient with Congenital Myotonia (CM) performed a home electrical
stimulation of the tibialis anterior muscle lasting 15 days with a frequency of two daily sessions of 60 minutes each.
Muscle strength was assessed according to the MRC scale (Medical Research Council) and functional tests (10 Meter
Walking Test, 6 Minutes Walking Test and Timed Up and Go Test) were performed. We analyzed the average
rectified value of sEMG signal amplitude (ARV) to characterize the sarcolemmal excitability.
Results: After the treatment an increase of muscle strength in those DM1 patients with a mild strength deficit was
observed. In all subjects an improvement of 10MWT was recorded. Five patients improved their performance in the
6MWT. In TUG test 4 out of 6 patients showed a slight reduction in execution time. All patients reported a
subjective improvement when walking. A complete recovery of the normal increasing ARV curve was observed in 4
out of 5 DM1 patients; the CM patient didn’t show modification of the ARV pattern.
Conclusions: NMES determined a clear-cut improvement of both the muscular weakness and the sarcolemmal
excitability alteration in our small group of DM1 patients. Therefore this rehabilitative approach, if confirmed by
further extensive studies, could be considered early in the management of muscular impairment in these patients.
An attractive hypothesis to explain our encouraging result could be represented by a functional inhibition of SK3
channels expressed in muscle of DM1 subjects.
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Myotonia refers to impaired muscle relaxation following
a voluntary forceful contraction. It is found in several
clinical disorders with different etiologies. Myotonic dys-
trophy type 1 (DM1) is the most common form of mus-
cular dystrophy in adults affecting approximately 1 in
8000. It is an autosomal dominant inherited disorder
with a peculiar and rare pattern of multisystemic clinical
features, affecting skeletal muscles, heart, eyes, endo-
crine and central nervous systems [1].
The genetic basis consist of an expansion of an un-
stable (CTG)n triplet repetition on chromosome 19 in
the 3’ un-translated region (3’-UTR) of the gene encod-
ing for myotonic dystrophy protein kinase (DMPK). The
abnormal repeated triplet is situated in a non-coding re-
gion of the gene, so it was suggested a loss of function
of DMPK protein, caused by either a transcriptional re-
pression or a gain of function mediated by the mutant
RNA transcripts. Currently, the best theory explaining
the pathogenesis focuses on RNA transcripts: in fact, in
DM1 cells were found multiple nuclear foci of mutant
DMPK-RNA, containing pathogenic CUG repeats, which
could produce defects in alternative splicing of multiple
RNAs, thus providing a basis for the multisystemic fea-
tures of DM1 [2].
The severity of the disease is proportional to the size
of the expansion. The number of repetitions tends to in-
crease from generation to generation, accounting for the
peculiar genetic anticipation of this disease [3-6].
Another myotonic disorder is Congenital Myotonia
(CM), an inherited myotonia due to a mutation in the
skeletal muscle chloride channel ClCN1 that leads to re-
duced sarcolemmal chloride conductance, which in turn
allows the muscle to be hyperpolarized, causing delayed
relaxation evident as clinical and electrical myotonia [7].
Muscle dysfunction is the most common presenting
complaint in DM1. Progressive muscle wasting and
weakness are hallmarks of DM1, even if the most char-
acteristic clinical feature of the disease is delayed relax-
ation of muscle due to repetitive action potentials, a
phenomenon called myotonia. Although not the most
serious complication of DM1, myotonia exacerbates dis-
ability, with preferential involvement of hands and fore-
arms [8].
There is no cure for DM1. Current treatment for DM1
is limited to supportive care that partially alleviates signs
and symptoms of the disease but does nothing to slow
or halt disease progression. To date, mexiletine, which
modulates sodium channels and thus lessens myotonia,
and Central Nervous System stimulants to address
fatigue, are the only useful drugs routinely applied in
practice [9]. At once, research in the field has led to sig-
nificant advances in understanding the complex patho-
physiology of the disease. Consequently, numerousapproaches to targeting disease mechanisms at each of
the steps in the pathogenesis at RNA level are demon-
strating great promise in pre-clinical studies [10].
In the last 10 years increasing attention has been paid
on rehabilitation in Neuromuscular Disorders but unfor-
tunately the data are not so strong to provide clear
guidelines [11].
The phenotypic expression of myotonia and dystrophy
is variously combined in patients and the pathophysio-
logical mechanism underlying the muscle impairment
remains unclear. Different pathophysiological hypothesis
have been formulated in this regard; overall, the impair-
ment is thought to be due to an alteration of the trans-
membrane ionic currents. Currently, the most shared
hypothesis attributes the hyperexcitability of skeletal
muscle to a reduced conductance of chloride channels
that leads to a sarcolemmal excitability alteration [12].
Using skeletal muscle from a transgenic mouse model of
DM1, Mankodi and colleagues [12] showed that expres-
sion of expanded CUG repeats in skeletal muscle re-
duces the transmembrane chloride conductance to levels
consistent with those expected to cause myotonia. Add-
itional studies determined that aberrant splicing of the
chloride channel ClCN1 resulted in loss of ClCN1 pro-
tein from the surface membrane [13]. Charlet and col-
leagues [14] demonstrated that CUG-Binding Protein
(CUG-BP), which is elevated in DM1 skeletal muscle,
binds to the ClCN1 pre-mRNA, and overexpression of
CUG-BP in transfected cells reproduces the aberrant
pattern of ClCN1 splicing. These groups propose that
disruptions in alternative splicing regulation of ClCN1
causes a channelopathy and membrane hyperexcitability,
leading to the classic DM1 feature of myotonia [12,14].
However, a very attractive theory is based on the
abnormal presence of small conductance Ca-activated
apamin-sensitive K + channels (SK3) in DM1 muscle
[15]. Calcium-activated potassium channels are an het-
erogeneous family widely distributed in neurones and
peripheral tissues, controlling repetitive firing in excit-
able cells and secretion in exo- and endocrine cells
[16,17]. A subset of this family are the small conduct-
ance ones (SK), first recorded at the single channel level
by Blatz & Magleby [18], voltage independent and found
to underlie the long lasting after-hyperpolarization
(AHP) following the action potential [19]. SK channels
are comprised of several types (SK1, SK2, SK3)
encoded by specific genes. SK3 channels are abnor-
mally expressed in DM1 muscle but not in CM muscle
[20]. They have been also revealed in myotubes and in
adult denervated muscle [21]. Interestingly, Beherens and
Vergara (1994) [22] showed that injection of apamin, a
bee venom toxin peptide which is a highly selective ligand
and functional blocker of SK channels, in the thenar emi-
nence muscles reduces EMG myotonic discharges in
Chisari et al. Journal of NeuroEngineering and Rehabilitation 2013, 10:94 Page 3 of 7
http://www.jneuroengrehab.com/content/10/1/94DM1. A similar effect has been demonstrated in our pre-
vious studies in which we showed that the local applica-
tion of apamin produces functional modifications in DM1
muscle both on needle EMG “myotonic runs” and on the
characteristic surface EMG pattern [23,24].
Very recently an interesting study in rats showed that
chronic Neuromuscular Electrical Stimulation (NMES) of
denervated soleus muscles determines down-regulation of
SK3 channels which are known to be expressed by adult
muscle after denervation [21,25].
NMES is a useful therapeutic tool in sport medicine
and in the rehabilitation of many clinical conditions
characterized by motor impairment [26,27] such as
stroke, cerebral palsy and spinal cord injury [28-30].
Starting from these assumptions, the aim of our study
was to evaluate the effects of a chronic electrical stimu-
lation protocol in a small group of DM1 patients both
on functional and electrical properties of muscle.Methods
Five DM1 patients (3 males and 2 females) and one pa-
tient with the dominant autosomal form of Congenital
Myotonia (CM) were enrolled (Table 1). The age range
was 28-65 years. Molecular DNA analysis for CTG trip-
let repetitions on chromosome 19 was performed in all
DM1 patients. The main clinical features of the patients
are summarized in Table 1. All subjects gave their informed
consent prior to testing and the study was approved by the
Ethical Committee of University Hospital of Pisa.Functional assessment
Patients were assessed for muscle strength of tibialis an-
terior (TA) according to the MRC scale (Medical Research
Council). Motor function was explored through the 10
Meter Walking Test (10MWT), the 6 Minutes Walking
Test (6MWT) and the Timed Up&Go Test (TUG).Table 1 Patient description and functional results
MRC 10MWT (min)
Patient Sex Age (years) T0 T1 T0 T1
1 DM1 M 35 5 5 7,54 5,34
2 DM1 F 28 4 5 8,18 6,87
3 DM1 M 65 4 5 8,98 6,25
4 DM1 M 28 4 5 11,89 11,5
5 DM1 F 58 3 3 15,3 14,4
6 CM M 39 5 5 8,43 7,88
Patients description, functional assessment and F Index before (T0) and after 15 day
CM Congenital Myotonia, MRC Medical Research Council, 10MWT 10 Meters Walking
m metres.Surface EMG assessment
Experimental procedure
Each subject was made to lie on a bed with one knee
fully extended and the relative ankle joint at 110°. The
motor points of the muscle were indentified as those
with the lowest stimulation threshold. The number of
motor points ranged from one to three: the most distal
one was used for the stimulation protocol.
The detection electrode was applied to previously
shaved skin cleansed with alchol. No conduction paste
was necessary. The electrode was moved over the
muscle in the area between the most distal motor point
and the tendon and was positioned, with an elastic strap,
with the two bar approximately perpendicular to the
Tibialis Anterior belly direction. A sensor for skin
temperature with a resolution of 0,1°C was fixed on the
skin, near the detection electrode, to check that skin
temperature did not change more than ±0,5°C during
the experiment. A pause of about 5 min was allowed be-
fore beginning the experimental phase in order to avoid
any fatigue effect.
Stimulated contractions were then performed with the
subjects relaxed and physically passive; the absence of
voluntary ME signals indicated this state.Motor point stimulation
We used a motor point stimulation protocol to characterize
sarcolemmal excitability according to previous study of
Chisari et al. [23,24].
Briefly, the stimulation was applied using a monopolar
technique with a negative, soaked-sponge electrode
(2 × 3 cm2) placed on the motor point and a large (8 ×
12 cm2) positive electrode on the gastrocnemius
muscle [31]. The frequency of stimulation was 35 Hz,
which is the highest one that records sequentially
muscle potential action without M-waves overlapping.
A supramaximal stimulation, 10-15% above the level6 MWT (m) TUG (min) F index values
T0 T1 T0 T1 T0 T1
364 402 8,78 8,75 0,59 -0,11
394 353 8,92 8,92 0,23 -0,06
411 465 8,1 8,22 0,3 -0,33
5 322 340 12,6 12,12 0,31 0,07
4 285 301 13,67 13,56 -0,23 -0,27
438 475 8,76 8,5 0,65 0,58
s (T1) of electrical stimulation protocol. DM1 Myotonic Distrophy type 1,
Test, 6MWT 6 Minutes walking Test, TUG Timed Up and Go test, min minutes,
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tential, measured through surface EMG M wave, was
then applied.
EMG recording
The myoelectric signal was detected by means of 2-bar
electrode. These bars, 10 mm long and 2 mm thick, are
10 mm apart and are fixed on a mildly flexible support.
A single differential output was obtained from the two
bars and was used to compute the myoelectric signal,
which was amplified, low-pass filtered with a cut-off fre-
quency of 480 Hz, digitized by a 12 bit analog-digital
converter and stored on the disk of a PC. The signal was
then tabulated and correlated with time for each stimu-
lated contraction.
We analyzed the average rectified value of EMG signal
amplitude (ARV) expressed in microvolts. We utilized
the DEM (Dispositivi Elettro Medicali – Torino – Italy)
Surface Myoelectric Signals Stimulation and Detection
System.
NMES protocol
The patients performed a home electrical stimulation of
the tibialis anterior muscle through a train of biphasic
rectangular pulses, duration of 0.1 msec, 20 Hz frequency
and supramaximal intensity. A bipolar stimulation tech-
nique was used, with electrodes placed along course of
muscle (negative electrode to proximal and positive elec-
trode to distal level) and fixed with self-adhesive strip. The
stimulation was intermittent, consisting of an active phase
of contraction (phase on) lasting 10 sec, followed by a
10 sec resting phase (phase off).
Treatment program lasted 15 days, with a frequency of
two daily sessions of 60 minutes each. The evaluations
were performed at T0 (before training) and T1 (after
15 days of training). Two patients (1 and 2) continued
the stimulation till 30 days (T2) In these patients the
sEMG signals were also recorded 15 days after suspen-
sion (T3).
Data analysis
Quantitative evaluation of the ARV pattern was
performed through computation of the F index (or area
ratio index), a regression-free muscle fatigue index based
on the rate of change of measured surface EMG vari-
ables described by Merletti et al. [32]. F index is the
product of a reference value (e.g., the first value of the
time series) and the time of observation defines a refer-
ence rectangle. The area between the upper side of such
rectangle and the experimental data points is divided by
the area of the reference rectangle to provide this index.
It is regression-free, it is dimensionless, it varies between
0 and 1 for decreasing patterns and it is negative for in-
creasing patterns [32].As previously reported by Chisari et al. [23] the sur-
face EMG amplitude parameter (ARV) exhibits an in-
creasing trend in normal subjects but a decreasing one
in DM1 patients, during prolonged contraction. Accord-
ingly, the F index assumes negative or positive values in
normal or pathological trends, respectively. The change
in the F index from positive to negative values was taken
as a criterion of the efficacy of the treatment.
Results
After treatment patients 2, 3 and 4 showed an increase
in muscle strength at T1 (MRC 4 to MRC 5); no change
was observed in other patients. In all subjects an im-
provement of 10MWT was recorded. In TUG test 4 out
of 6 patients (patients 1, 4, 5 and 6) showed a slight re-
duction in execution time. Five patients, (patients 1, 3, 4,
5, 6) improved their performance in the 6MWT
(Table 1). All patients reported a subjective improve-
ment when walking.
As regard the EMG assessment (Figure 1), patients 1,
2, 3, 4 and 6 showed the typical decreasing ARV pattern
at T0 whereas patient 5 exhibited an increasing trend (as
expected because of his severe strength deficit). A clear
and complete recovery of the normal increasing ARV
curve was observed at T1 in pts 1, 2, 3 and 4, with F
index changing from positive to negative value. In pa-
tients 1 and 2 a normal ARV trend, with a negative F
index, could still be recorded at T2. Recording of ARV
at T3 (15 days after the end of stimulation) showed a
trend toward a pathological pattern with the F index
coming back to a positive value. Patients 5 and 6 did not
show modification of the ARV pattern at T1, data con-
firmed by an unchanged F Index (Table 1).
Discussion
The results of this pilot study show that neuromuscular
electrical stimulation (NMES) in patients affected by Myo-
tonic Dystrophy type 1 and Congenital Myotonia deter-
mines a clear improvement of muscular impairment.
The improvement of muscle strength observed after
the treatment in those DM1 patients with a mild
strength deficit is a very important clinical datum per se.
Indeed, they present a high risk of falls because of weak-
ness in specific muscle groups (for example knee exten-
sors and mostly ankle/toe dorsi-flexors) [33]; therefore,
an early intervention through NMES could be a funda-
mental approach in order to reduce this risk.
On the other hand we observed after the treatment an
improvement in the 10MWT, meaning an increase in
walking velocity, in all patients. 5 out 6 patients showed
a better performance in the 6MWT.
Finally in 4 pts we recorded a reduction in time to
complete the Timed Up and Go Test. This test involves
a higher number of muscle group and this could explain
Figure 1 Normalized ARV values before and after the treatment. ARV = Average Rectified Value of EMG signal amplitude. On the x axis is
represented Time (in seconds); on y axis is represented the ARV value. In the figure legend, T0 = before training; T1 = after 15 days of training;
T2 = after 30 days of training; T3 = 15 days after suspension.
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tients. We have to keep in mind that we stimulated
the Tibialis Anterior muscle that is a very important
muscle for walking but is not so influent to stand up
from a chair.
These functional findings, though obtained in a limited
number of subjects and showing a transient effect, seem
very interesting because of their possible effect on the
Quality of Life of DM1 and CM patients.
An effect on sarcolemmal excitability of DM1 patients
is demonstrated by the sEMG assessment which showed,
after the NMES protocol, a clear and complete recovery
of the normal increasing ARV curve at T1 in patients 1,
2, 3, 4. A normal ARV trend could still be recorded at
T2 in patients 1 and 2. Patient 5 (the patient with the
most severe strength deficit, as shown by MRC), as
expected because of her increasing trend at T0, and CM
subject (pt 6) didn’t show modification of the ARVpattern. In previous studies Chisari et al. [24] found a
clear-cut relationship between the ARV trend and the
sarcolemmal excitability alteration and/or the myofibre
degeneration contributing to muscle impairment in DM1.
In particular, a decreasing ARV trend (typical of patient
without strength deficit or with a mild one) is closely re-
lated to the sarcolemmal excitability alteration whereas a
normal increasing trend, observed in those patients with
severe strength deficit, refers to a reduced number of
myofiber and/or to the atrophic process, characteristic of
DM1 muscle in the later phase of the disease. Therefore
the rescue of a normal EMG pattern in DM1 patients 1, 2,
3, 4 and the lack of effect in patient 5 indicates the specifi-
city of the effect of NMES on the membrane excitability.
Moreover the EMG pattern of CM patient did not show
any change after the stimulation. This suggests an effect
on a membrane excitability defect which is peculiar of
DM1.
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parameters and time modulations variously combined
in order to induce muscle contraction that aim to
stimulate both endurance and strength training [26,27].
The selection of stimulation parameters is typically
based on each patient’s rehabilitation goal. For example,
stimulation frequencies <15 Hz help increasing aerobic
capacity in patients with heart failure while stimulation
frequencies >50 Hz are able to increase muscle strength
[31]. The mechanisms underlying these effects have
been studied extensively and they seem to be due to dif-
ferent processes as an increase of cross-sectional area of
the stimulated muscle [31], an activation of additional
motor units [34] and a metabolic activation of muscle fi-
bres through an increase in the number of cross-bridges
between actin and myosin myofilaments [35].
Giving an exhaustive explanation of the operating
mechanism by which NMES acted in our patients is dif-
ficult, as we adopted an unusual frequency stimulation
and as we do not have histological and/or molecular
data of the treated muscles. A cooperation of all the fac-
tors mentioned above could have occurred. Neverthe-
less, another attractive hypothesis comes out from the
parallelism with a recent study on a denervated muscle
animal model [25] which showed that chronic stimula-
tion in vivo is able to revert the denervation-induced
up-regulation of SK3 channels expression. In that ex-
periment chronic electrical stimulation of denervated
muscles also completely prevented the development of
the after-hyperpolarization (AHP) following the action
potential, normally induced in the muscle fibers by
denervation.
On this background an interesting speculation to ex-
plain our encouraging result obtained in DM1 patients
could be represented by a functional inhibition and/or a
down regulation, by means of NMES, of SK3 channels,
abnormally expressed in muscle of these patients. This
hypothesis is reinforced by the evidence of inefficacy of
the treatment on the EMG pattern recorded in CM pa-
tient; in fact in CM muscles is not documented the ab-
normal expression of SK3 channels [20].
Of course further studies are necessary in order to ver-
ify this suggestive hypothesis. Future tests should take
into account the study of Rhodes et al. [36] describing
the effect of apamin, a highly selective ligand and func-
tional blocker of SK channels, on DM1 lens cell lines
[36]. These authors found an increased resistance in
subsequent culture transfers and therefore a higher
survival in cell lines incubated with apamin. They con-
cluded that apamin protects the cell lens from degener-
ation. Moreover they suggested that also atrophy and
degeneration of muscle tissue could be due to SK3 chan-
nels expression. Considering these data of Rhodes et al.
[36], the availability of a rehabilitative tool able tointerfere with the expression of SK3 channels could have
a possible preventive action on the “dystrophic” evolu-
tion of the disease.
Conclusions
In conclusion, the results of our pilot study show that
Neuromuscular Electric Stimulation in patients affected
by Myotonic Dystrophy type 1 determines an improve-
ment of both the muscular weakness and the sarcolem-
mal excitability alteration. This new therapeutic
approach could be able to reduce the risk of falls in
these patients. It can be comfortably performed at home,
therefore could be considered early in the management
of muscular impairment in DM1. Of course we cannot
disregard that we examined a small group of patients
and a largest cohort of patients have to be investigated
to confirm these data. Moreover no molecular studies
have been performed in order to clarify the intrinsic ef-
fect of NMES. But, if our pathogenetic hypothesis were
confirmed, it would be desirable to intensify the research
about a feasible preventive role of this rehabilitative
method on DM1 progression.
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